Your shopping cart is currently empty

SIAIS178 is a selective PROTAC degrader targeting BCR-ABL with an IC50 of 24 nM. It degrades BCR-ABL protein by recruiting the VHL E3 ubiquitin ligase, inhibiting leukaemia cell growth in vitro and causing regression of K562 xenograft tumours.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | - | In Stock | |
| 5 mg | $396 | - | In Stock | |
| 10 mg | $538 | - | In Stock | |
| 25 mg | $987 | - | In Stock | |
| 50 mg | $1,590 | - | In Stock | |
| 100 mg | $2,280 | - | In Stock | |
| 200 mg | $2,970 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $436 | - | In Stock |
| Description | SIAIS178 is a selective PROTAC degrader targeting BCR-ABL with an IC50 of 24 nM. It degrades BCR-ABL protein by recruiting the VHL E3 ubiquitin ligase, inhibiting leukaemia cell growth in vitro and causing regression of K562 xenograft tumours. |
| Targets&IC50 | VHL:24 nM, BCR-ABL:24 nM |
| In vitro | Methods: K562 cells were treated with SIAIS178 (1, 3, 10, 30, 100 nM, 16 hours) and BCR-ABL protein expression was detected by Western blot. Results: SIAIS178 significantly reduced BCR-ABL protein levels in a concentration-dependent manner. [1] |
| In vivo | Methods: SIAIS178 (5, 15, and 45 mg/kg) was used to treat K562-Luc NOD/SCID mice and investigate its effect on tumor progression in vivo. Results: SIAIS178 attenuated tumor progression in a dose-dependent manner as determined by serial volume measurements. [1] |
| Synonyms | SIAI S178 |
| Molecular Weight | 1012.68 |
| Formula | C50H62ClN11O6S2 |
| Cas No. | 2376047-73-1 |
| Smiles | C([C@@H](NC(CCCCCCC(=O)N1CCN(CC1)C=2C=C(NC=3SC(C(NC4=C(C)C=CC=C4Cl)=O)=CN3)N=C(C)N2)=O)[C@](C)(C)C)(=O)N5[C@H](C(NCC6=CC=C(C=C6)C7=C(C)N=CS7)=O)C[C@@H](O)C5 |
| Relative Density. | 1.335 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 245 mg/mL (241.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (4.94 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.